sb-223245 and Osteoporosis

sb-223245 has been researched along with Osteoporosis* in 1 studies

Other Studies

1 other study(ies) available for sb-223245 and Osteoporosis

Article	Year
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorganic & medicinal chemistry letters, 1999, Jul-05, Volume: 9, Issue:13 A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis. Topics: Acetates; Administration, Oral; Aminopyridines; Animals; Benzodiazepinones; Biological Availability; Disease Models, Animal; Kinetics; Osteoporosis; Rats; Receptors, Vitronectin; Time Factors	1999

Article

Year

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Bioorganic & medicinal chemistry letters, 1999, Jul-05, Volume: 9, Issue:13

A new series of potent nonpeptide vitronectin receptor antagonists, based on a novel carbocyclic Gly-Asp mimetic, has been discovered. A representative of this series, SB 265123 (4), has 100% oral bioavailability in rats, and is orally active in vivo in the ovariectomized rat model of osteoporosis.

Topics: Acetates; Administration, Oral; Aminopyridines; Animals; Benzodiazepinones; Biological Availability; Disease Models, Animal; Kinetics; Osteoporosis; Rats; Receptors, Vitronectin; Time Factors

1999